- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
GE payment lifts Fonar results
Fonar's ship finally came in this month when the Melville, NY, company released fourth-quarter and year-end financial results that show the impact of the firm's victory over GE Medical Systems in MRI patent litigation. Fonar reported net income of $56.1
Fonar's ship finally came in this month when the Melville, NY, company released fourth-quarter and year-end financial results that show the impact of the firm's victory over GE Medical Systems in MRI patent litigation. Fonar reported net income of $56.1 million for the year, and the formerly cash-strapped company now has a working capital surplus of $62.7 million.
GE paid Fonar $128.7 million in July for the judgment, of which Fonar kept $77.2 million. The rest of the money went for lawyer's fees and related expenses. The U.S. Supreme Court declined to hear GE's appeal of the case earlier this month (SCAN 10/15/97).
The $56.1 million net income figure compares with a net loss of $11.4 million for fiscal 1996. Fonar posted 1997 revenues of $17.6 million, up 27% compared with sales of $13.9 million the year before. The company's backlog as of Sept. 1 was $6.4 million, compared with $6.8 million at the same time in 1996.
Fonar said it will use its new-found cash to pursue new MRI applications, such as MR-guided surgery and MR mammography. In addition, Fonar has expanded into the physician practice management business through its U.S. Health Management subsidiary. Some of the cash will also be spent on a stock repurchasing effort that Fonar began this month.
FDA Approves Fluorescence Imaging System for Detecting Residual Breast Cancer
April 18th 2024The combination of the optical imaging agent Lumisight and the fluorescence imaging device Lumicell Direct Visualization System, collectively known as LumiSystem, reportedly offers 84 percent accuracy with real-time detection of residual breast cancer after lumpectomy procedures.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.
Could a Deep Learning Model for Mammography Improve Prediction of DCIS and Invasive Breast Cancer?
April 15th 2024Artificial intelligence (AI) assessment of mammography images may significantly enhance the prediction of invasive breast cancer and ductal carcinoma in situ (DCIS) in women with breast cancer, according to new research presented at the Society for Breast Imaging (SBI) conference.
